מן הרשת

עמוד 9 מתוך 28
<
1
...
4
5
6
7
8
9
10
11
12
13
...
28
>

22.06.2020

13:56

Long-term efficacy of erenumab in chronic migraine

patients with or without acute medication overuse

Neurology

21.06.2020

17:46

FDA Approves Lurbinectedin for Metastatic Small Cell Lung Cancer

The FDA has approved lurbinectedin (Zepzelca) for the treatment of adult patients with metastatic small cell lung cancer with disease progression, following platinum-based chemotherapy

OncLive

15.06.2020

15:24

Treatment of infertility and menopause in a patient with multiple sclerosis affecting the pituitary stalk: a case report

In this patient population, infertility treatment can be successful with gonadotropins and alleviation of menopausal symptoms can be achieved with hormone replacement

Global Reproductive Health

15.06.2020

15:21

Coronavirus Disease 2019 (COVID-19) and Pregnancy

Combating Isolation to Improve Outcomes

Obstet Gyneco

15.06.2020

15:19

Aspirin for primary prevention of cardiovascular disease in women

For primary prevention, low-dose aspirin should be considered in women aged 40 to 70 years with a 10-year cardiovascular risk of 20% or more or in women with diabetes and a 10-year cardiovascular risk of 10% or more. The risk of bleeding outweighs the benefits in low-risk women and in women aged 70 years and older

Menopause: The Journal of The North American Menopause Society

11.06.2020

11:40

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non–small-cell lung cancer

NEJM

31.05.2020

17:43

Localized Prostate Cancer Management in the Time of COVID-19

The rapid spread of Coronavirus Disease 2019 (COVID-19) throughout the world, caused by the betacoronavirus SARS-CoV-2, has had dramatic effects on health care systems with impacts far beyond the patients actually infected with COVID-19

UroToday

31.05.2020

17:41

The Risks of Delaying Kidney Cancer Treatment During COVID-19

The rapid spread of Coronavirus Disease 2019 (COVID-19), caused by the betacoronavirus SARS-CoV-2, has had dramatic effects throughout the world on healthcare systems with impacts far beyond the patients actually infected with COVID-19

31.05.2020

17:40

Risks of Delaying Bladder Cancer Diagnosis- Surveillance and Surgery During COVID-19

The rapid spread of Coronavirus Disease 2019 (COVID-19), caused by the betacoronavirus SARS-CoV-2, throughout the world has had dramatic effects on healthcare systems with impacts far beyond the patients actually infected with COVID-19

UroToday

31.05.2020

17:38

Adjuvant Chemotherapy Shows Strong Benefit in Upper Tract Urothelial Carcinoma

Adjuvant platinum-based chemotherapy reduced the risk of disease recurrence or death by 55% in patients with upper tract urothelial carcinoma (UTUC), according to findings from the phase III POUT trial that have now been published in The Lancet

OncLive

31.05.2020

17:36

FDA Approves Mitomycin Gel for Urothelial Cancer

The FDA has approved mitomycin gel (UGN-101; Jelmyto) as the first therapy to treat low-grade upper tract urothelial cancer

OncLive

31.05.2020

17:16

Savolitinib Shows Promising Efficacy Data in Papillary Renal Cell Carcinoma

Savolitinib showed encouraging efficacy data and an improved safety profile compared with sunitinib (Sutent) as a treatment for patients with MET-driven papillary renal cell carcinoma (RCC), according to results that were presented during the 2020 ASCO Virtual Scientific Program

OncLive

31.05.2020

17:11

Tivozanib Showcases Superiority in Relapsed/Refractory RCC

Tivozanib (Fotivda) demonstrated a significant improvement in progression-free survival (PFS) compared with sorafenib (Nexavar), with similar overall survival (OS), in patients with highly relapsed.refractory metastatic renal cell carcinoma (RCC), according to results of the phase 3 TIVO-3 trial presented at the 2020 ASCO Virtual Scientific Program

OncLive

31.05.2020

17:09

Adjuvant Atezolizumab Misses DFS Endpoint in Muscle-Invasive Bladder Cancer

Adjuvant treatment with atezolizumab (Tecentriq) did not significantly improve disease-free survival (DFS) compared with observation in patients with muscle-invasive bladder cancer, missing the primary endpoint of the phase III IMvigor010 trial

OncLive

31.05.2020

17:08

FDA Approves Olaparib for HRR-Mutant mCRPC

The FDA has approved olaparib (Lynparza) for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide (Xtandi) or abiraterone acetate

OncLive

עמוד 9 מתוך 28
<
1
...
4
5
6
7
8
9
10
11
12
13
...
28
>